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Background: Human hepatoma HepG2 cells are used as an in vitro model of the human liver. High-throughput
transcriptomic sequencing is an advanced approach for assessing the functional state of a tissue or cell type. However,
the influence of experimental factors, such as the sample preparation method and inter-laboratory variation, on the
transcriptomic profile has not been evaluated.
Results: The whole-transcriptome sequencing of HepG2 cells was performed using the SOLiD platform and validated
using droplet digital PCR. The gene expression profile was compared to the results obtained with the same sequencing
method in another laboratory and using another sample preparation method. We also compared the transcriptomic
profile HepG2 cells with that of liver tissue. Comparison of the gene expression profiles between the HepG2 cell line
and liver tissue revealed the highest variation, followed by HepG2 cells submitted to two different sample preparation
protocols. The lowest variation was observed between HepG2 cells prepared by two different laboratories using the
same protocol. The enrichment analysis of the genes that were differentially expressed between HepG2 cells and liver
tissue mainly revealed the cancer-associated gene signature of HepG2 cells and the activation of the response to
chemical stimuli in the liver tissue. The HepG2 transcriptome obtained with the SOLiD platform was highly correlated
with the published transcriptome obtained with the Illumina and Helicos platforms, with moderate correspondence
to microarrays.
Conclusions: In the present study, we assessed the influence of experimental factors on the HepG2 transcriptome and
identified differences in gene expression between the HepG2 cell line and liver cells. These findings will facilitate robust
experimental design in the fields of pharmacology and toxicology. Our results were supported by a comparative
analysis with previous HepG2 gene expression studies.
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Human cell lines are widely used to accurately assess the
toxic properties and activities of both novel and well-
known chemical entities. These experiments are important
for the pharmaceutical, chemical, medical and cosmetic in-
dustries. Typically, cell line-based assays are preferred to
those based on animal models, reflecting the low cost, high* Correspondence: at@niifhm.ru
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One of the most frequently modeled organs of the human
organism is the liver, a central organ for the maintenance
of chemical homeostasis that participates in the synthesis
of proteins and detoxification.
The human hepatoma HepG2 cell line (ATCC HB-8065)
has been widely used as an in vitro model of the human
liver because these cells display a high degree of morpho-
logical and functional differentiation in vitro, are easy to
handle, do not contain viruses and generate reproducible
results. This cell line was recovered from a 15-year-oldThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Comparison of gene expression levels using RNA-Seq.
The RNA-Seq (RPKM values, for HI1 sample) and ddPCR data
(number of copies per 1 μg of total RNA) are compared for 45 genes
(with pseudocount of 0.1 added, log2). The color of the dots reflects
the binning of the respective genes by their log2 fold change (L2FC)
in the comparison of HepG2 cell line vs. liver using SOLiD RNA-Seq;
for each bin, the number of the genes and Spearman correlation is
included. Only the genes identified as differentially expressed
are shown.
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While new promising liver models like pluripotent
stem cell-derived hepatocyte-like cells are becoming
available [1], HepG2 cells have been used in toxico-
logical studies of liver metabolism and the toxic effects
of xenobiotics and in pharmacological studies on drug
targeting and carcinogenesis [2].
Gene expression profiling is a powerful tool that has
provided numerous insights in previous studies. While
RT-PCR and microarrays are commonly used to assess tran-
scriptomic activity, whole-transcriptome high-throughput
sequencing (RNA-Seq) provides the most extensive evalu-
ation, with a wide dynamic range and higher sensitivity
[3,4]. Considering the high cost of experiments based on
this technology, a thorough experimental design is im-
portant. Here, we performed a rigorous assessment of the
contribution of each of the main experimental factors
ceteris paribus to the gene expression profile and com-
pared the results with those reported in existing studies
performed using another RNA-Seq platform (Illumina)
and previous technology (microarrays). In addition, we
derived a characteristic signature for the HepG2 tran-
scriptome compared with liver tissue via differential
gene expression analysis, and these results were also
compared with previously published results obtained
using microarrays.Results
Whole transcriptome of the HepG2 cell line
The 3 technical replicates, HI1, HI2, and HI3, contained
208, 132 and 149 million reads, respectively, with a read
length of 50 bp. At the filtering stage, 2.3-4.1% of the total
number of reads that aligned with the sequences of human
rRNA and SOLiD adapters were discarded. Subsequently,
68%-75% of the reads were successfully mapped to the
human genome. More than 17,000 genes were expressed
in each sample (18,923 genes when all the replicates
were pooled together).Validation using ddPCR as a complementary approach
Droplet digital polymerase chain reaction (ddPCR) is a
new technology that facilitates the quantification of target
nucleic acids in a sample [5]. For the HepG2 cell line, the
ddPCR was implemented to measure 45 selected RNA
transcripts. The gene copy number per 1 μg of total RNA
varied from 0 to 2,576,000 (Additional file 1: Table S1).
A good correlation was observed between the ddPCR
and the RNA-Seq three replicates in general (Spearman
r = 0.943 ± 0.001), as well as when the genes were binned
according to their fold change between HepG2 cell line
and liver, as detected by SOLiD RNA-Seq, as described
below (Figure 1).Variation of the transcriptomic profile between the
technical replicates and between samples prepared using
different methods or different culturing conditions and
comparison with liver tissue
For the comparative analysis, we compared the three
technical replicates, HI1-3, obtained from a sample cul-
tured at the IBMC with the two RNA-Seq SOLiD data-
sets generated from a single RNA sample extracted from
a HepG2 cell line cultivated at the Research Institute of
Physico-Chemical Medicine (RIPCM) in 2011: the first
previously unpublished library (id: HR_m, 1 technical
replicate) was prepared as described in the Methods sec-
tion (method M here and below), while the second pub-
lished library [6] (id: HR_c, 1 technical replicate) was
prepared using a different protocol (method C here and
below; see Additional file 2: Table S2). In the present
study, we also included liver transcriptomes obtained
with the SOLiD platform (two technical replicates, ids:
L1, L2) [7] using method M. Because the data were ob-
tained on identical platforms using identical formats
(SOLiD 4 whole-transcriptome, fragment library, 50 bp
reads), we were able to assess the contribution of each
of the experimental factor to the quantitative transcrip-
tomic profile. The summary of the SOLiD samples is
shown in Table 1. To assess the general variation of gene
expression across sequencing platforms, we included two
Illumina datasets - one from the ENCODE project [8]
(HepG2 cell line, 1 readset, “Transcript Gencode V3c”
Table 1 Description of the samples sequenced on the SOLiD 4 platform
Biological object Source, date of cultivation
and sequencing




Publication and SRA reference
HepG2 cell line IBMC, 2013 HI: HI1, HI2, HI3 M previously unpublished, SRR1047450
HepG2 cell line RIPCM, 2011 HR: HR_m M previously unpublished, SRR1254936
HepG2 cell line RIPCM, 2011 HR: HR_c C [6], SRR547993
Liver tissue IBMC, 2012 L: L1, L2 M [7], SRR830334
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in GTF format, GEO sample GSM958732) and another
from van Delft et al. [9] (HepG2 cell line - control sample,
1 dataset; GEO sample GSM884985).
All other factors held equal, the lowest Spearman cor-
relation of RPKM values was observed between the
HepG2 cell line and liver tissue (group HI + HR_m vs.
group L; r = 0.67 ± 0.02; Figure 2). The next most dis-
similar datasets were derived from HepG2 cells prepared
using different protocols (HR_m vs. HR_c; r = 0.78),
followed by the HepG2 samples from two different la-
boratories (group HI vs. HR_m; r = 0.96 ± 0.01). The
technical replicates were the most strongly correlated
(within group HI; r = 0.99 ± 0.01).
Comparison of different HepG2 transcriptomes
The effects of experimental conditions and sample prep-
aration were evaluated by the identification of the genes
that were differentially expressed across the correspond-
ing pairs of HepG2 datasets. To assess the “laboratory
effect”, we compared the HepG2 transcriptomes pre-
pared using the same protocol (method M) originatingFigure 2 Dissimilarity heatmap showing the clustering of the transcri
metric: 1 - Spearman correlation between the levels of the genes with RPK
numbers reflect pairwise correlation values.from laboratories at two different research institutes -
IBMC and RIPCM: group HI (the three technical replicates
were pooled into one dataset) and HR_m, respectively.
Consistent with the general high correlation, most of the
expressed genes varied moderately between the datasets,
with a log2-fold change of 0.51 ± 0.47 (median ± s.d.; for the
6,947 genes expressed in both datasets with RPKM> 10 in
at least one of them). For the 17 housekeeping genes listed
in Additional file 3: Table S3, the variation was even lower,
showing a log2-fold change of 0.45 ± 0.35 (TUBB gene
with zero RPKM values was omitted here; see Additional
file 4: Table S4a). The most variable genes (with a fold-
change higher than 3) included 70 genes that were up-
regulated and 130 genes that were down-regulated in the
HI group (Additional file 4: Table S4b) and enriched for
small nucleolar RNAs (21% of the differentially expressed
genes).
Similarly, to assess the influence of the sample prepar-
ation on the gene expression profile, we compared the
HepG2 transcriptomes obtained from the same physical
sample prepared using two protocols: method M (dataset
HR_m) and method C (dataset HR_c). The differencesptome samples based on the gene expression levels. Distance
M > 0.1 in at least one sample; tree constructed using Ward linking; the
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(Mann-Whitney’s one-sided test, P < 2.2E-16): the log2-
fold change for the most highly expressed genes between
the datasets was 1.46 ± 2.16 (for the 7,024 genes expressed
in both datasets with RPKM> 10 in at least one of them),
and the expression of the housekeeping genes was also
profoundly changed: the log2-fold change was 0.69 ± 1.29
(similarly, the TUBB gene was also omitted here; Additional
file 4: Table S4c). The list of the most variable genes
(with fold-changes higher than 3) was more extensive
and included 2,374 genes that were up-regulated and
878 genes that were down-regulated in HR_m (Additional
file 4: Table S4d). The GO enrichment analysis gener-
ated several enriched terms with low adjusted p-values
(adjP < 0.05); however, the ratio of enrichment, reflect-
ing the effect size, was quite low (R < 1.55). Therefore,
the underlying biological effect of these differences was
not significant.
In order to compare the HepG2 transcriptome ob-
tained using amplification-based platform (SOLiD) with
the single-molecule sequencing, we sequenced HepG2
cell line transcriptome on Helicos platform. After calcu-
lation of gene expression levels, due to the wide range of
order of gene expression level magnitude the genes were
binned according to their fold change between HepG2
cell line and liver, as detected by SOLiD RNA-Seq, as
described below; the bin-wise correlation was high
(0.87 ± 0.12; see Additional file 5: Table S5). Another
cross-platform validation was performed by comparing
the HepG2 transcriptomes obtained in the present
study using SOLiD with the previously published
RNA-Seq data obtained from other research groups on
an Illumina platform. The HI_1 dataset was selected as
a representative of the HI group, and these data were
highly correlated with the HepG2 transcriptome from
the ENCODE project (Spearman correlation r = 0.92, for
RPKM vs. FPKM of 18,831 genes resulting after the anno-
tation conversion from RefGene to Ensembl; Additional
file 6: Table S6 and Additional file 7: Figure S1). Similarly,
HI_1 was highly correlated with the RNA-Seq data from
van Delft et al. [9] (r = 0.90, for 18,986 genes).
In addition, we compared the RNA-Seq data obtained
in the present study with the published In addition, we
compared the RNA-Seq data obtained in the present
study with the published HepG2 transcriptomes obtained
using RNA expression microarrays. A search of the GEO
database yielded four studies (GSE5230, GSE6878,
GSE6907, GSE9166 – using Affymetrix Human Gen-
ome U133 Plus 2.0 Array, Affymetrix Human Genome
U133 Plus 2.0 Array, Affymetrix Human HG-Focus
Target Array and Affymetrix Human Genome U133A
Array, accordingly) containing the microarray gene ex-
pression profiles for 14 control HepG2 samples. The
correlation of these profiles with the RNA-Seq HepG2data obtained herein was modest, but it was higher
than the correlation with the liver data (0.76 ± 0.04 vs.
0.58 ± 0.03; Additional file 6: Table S6 and Additional
file 7: Figure S1). The transcriptomes obtained using
method M were slightly more similar to the microarrays
than the data obtained using method C (0.77 ± 0.04 vs.
0.73 ± 0.04).
Hepatocarcinomic signature of HepG2 gene expression
profile
Differential gene expression analysis was performed be-
tween the liver tissue and HepG2 transcriptomes. The
liver group included L1 and L2, while HepG2 was repre-
sented by two samples from two laboratories treated as
biological replicates: HR_m originated from the RIPCM
laboratory, and HI1 - HI3 originated from the IBMC la-
boratory. The availability of more than one biological
replicate of HepG2 in one of the groups allowed the ap-
plication of the statistical model from the edgeR pack-
age. We performed a genewise exact test for differences
in the means (with prior.df parameter set to 50) to iden-
tify the most significant variations. Before the analysis,
all respective technical replicates were pooled. Only
15,139 genes covered by >100 reads in at least one sam-
ple were considered. With an FDR-adjusted p-value
threshold of 0.1, 658 genes were identified as differen-
tially expressed (notably, none of the 18 previously de-
scribed housekeeping genes were included).
Fifty of these genes were up-regulated in HepG2 cells
(Additional file 8: Table S7a). The enrichment analysis of
the GO terms using WebGestalt (Additional file 9: Table
S8a) yielded 40 significantly enriched biological pro-
cesses (adjP < 0.05). The enriched terms included genes
involved in the cell cycle (GO:0007049, adjP = 4.10E-07)
and cell division (GO:0051301, adjP = 1.29E-08). On a
more detailed level, the processes related to mitotic cell
division were predominant (GO:0000087, adjP = 1.91E-11).
Particularly, the genes responsible for chromosome con-
densation, organelle fission and microtubule cytoskeleton
organization were overexpressed. The observed phenomena
were obviously associated with the active division of HepG2
cells.
From a different angle, the WebGestalt analysis of the
associations between the 50 up-regulated genes and dis-
eases showed Aneuploidy among the 10 most enriched
disease terms (each of which had adjP ≤ 0.005, Additional
file 9: Table S8b) (6 genes), Adenoma (6), Chromosome
Aberrations (6), Liver Neoplasms (4) and Hepatocellular
Carcinoma (4), suggesting an association of these genes
with the oncological status of HepG2 cells. To confirm
this finding, we characterized the potential associations
between the up-regulated genes in HepG2 cells and hepa-
toma using the liver cancer-related gene signature data-
base, Liverome [10]. For 28 of the 50 genes, increased
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healthy controls, and this increase is associated with
the aggressiveness of the tumor and a worse prognosis
(this evidence was supported by an average of 4 studies
per gene among the 143 publications present in Liver-
ome). These associations from the existing studies also
reflected the fact that HepG2 cells are derived from a
hepatocarcinoma.
Response to stimulus is reflected by the gene expression
in the liver
The analysis of the 608 genes up-regulated in the liver
compared with the HepG2 cell line (Additional file 8:
Table S7b) identified 40 enriched GO biological pro-
cesses (adjP < 0.05, Additional file 9: Table S8c). The
highest number of the genes (337/608, 55.3%) belonged
to the term “response to stimulus” (GO:0050896, adjP =
4.16E-21). On a lower level, 192 of these genes were asso-
ciated with “response to chemical stimulus” (GO:0042221,
adjP = 4.64E-22), particularly, the 39 genes for “xenobiotic
metabolic process” (GO:0009410, adjP = 3.19E-21). The
activation of the defense response genes was also observed
(99 genes are in GO:0006952, adjP = 9.13E-17).
Another large enriched term was “small molecule meta-
bolic process” (168 genes in GO:0044281, adjP = 5.20E-17),
including the 81 genes involved in carboxylic acid metabol-
ism (GO:0019752, adjP = 5.55E-15), particularly monocar-
boxylic acid metabolism (55 genes, GO:0032787, adjP =
3.98E-16). Carboxylic acid metabolism is activated in re-
sponse to the need to provide energy for the detoxification
processes and secretory activities of the liver (synthesis
and secretion of biologically active substances and blood
plasma components), and the cell “boosts” its metabolism
to synthesize ATP at an increasing rate. Moreover, carbox-
ylic acids are involved in the biosynthesis of cholesterol,
10% of which is produced in the liver as a precursor for
the synthesis of bile acids and steroid hormones.
Consistently, processes associated with electron carrier
(25 genes, GO:0009055, adjP = 3.16E-09) and oxidoreduc-
tase activities (62 genes, GO:0016491, adjP = 1.72E-10),
primarily provided through the liver cytochrome system,
are predominant. The high excretory-secretory activity
in the tested liver tissue cells was mirrored by the in-
creased expression of the extracellular region (179 genes,
GO:0005576, adjP = 2.35E-33) and extracellular matrix
(48 genes, GO:0031012, adjP = 3.14E-12) genes. Activa-
tion of these genes is primarily caused by the expression
of the cell surface receptors, the production of blood
plasma components, the complement system and inter-
leukins. Furthermore, the enrichment of collagen synthesis
(21 genes, GO:0005581, adjP = 3.15E-11) is a logical con-
sequence of hepatocyte physiology.
Consistent with the results obtained for the GO terms,
the 10 most enriched KEGG pathways (each of whichhad adjP ≤ 1E-11) included “Drug metabolism - cyto-
chrome P450”, “Metabolism of xenobiotics by cyto-
chrome P450” and “Drug metabolism - other enzymes”
(Additional file 9: Table S8d). Moreover, the increased
expression of the genes involved in the “Retinol metab-
olism” pathway is consistent with the breakdown of
dietary vitamin A (all-trans-retinol) in the small intes-
tine and the release of retinol. Retinol is transported to
the liver in the form of chylomicrons where it is con-
verted into retinyl esters that are accumulated in liver
cells [11].
Among other KEGG pathways, the observed enrich-
ment of the “Steroid hormone biosynthesis” pathway pri-
marily reflects the presence of enzymes responsible for
steroid and bilirubin inactivation, another physiological
function of the liver. The cholesterol synthesis enzymes
were also up-regulated. The up-regulation of the “Com-
plement and coagulation cascades” pathway also reflects
the physiological function of the liver, involving the synthe-
sis and secretion (excretion) of essential plasma proteins,
including the complement system and clotting factors.
Discussion
Transcriptomic profiling based on high-throughput se-
quencing (RNA-Seq) facilitates the analysis of gene ex-
pression at an unprecedented high dynamic range. Global
initiatives, including ENCODE, have provided an exten-
sive inventory of human tissues and helped to identify dif-
ferentially expressed genes with subsequent applicability
in clinical practice. We applied RNA-Seq using a SOLiD 4
platform for deep transcriptomic profiling of HepG2 cells,
a widely used laboratory cell line. A large amount of tran-
scriptomic data for HepG2 cells is available, and most of
these data have been generated using RNA hybridization
microarrays. Recently, HepG2 transcriptomes have been
examined using high-throughput sequencing on the Illu-
mina [8,9] and SOLiD [6,7] platforms. The experiments
described herein were performed on a single platform
(SOLiD 4) using the same sequence format to eliminate
the choice of platform as a confounding factor and focus
on the influence of the other experimental factors for the
evaluation of the HepG2 transcriptome and the determin-
ation of transcriptomic differences between the liver and
HepG2 cells as a model system for this organ.
A comparison of the transcriptomic data obtained using
the same sequencing platform revealed that the sample
and sequencing library preparation protocol, not the
“laboratory effect” as expected, had the highest contribu-
tion to the HepG2 gene signature. The minor differences
in the expression profiles between the laboratories (HI vs.
HR_m) likely reflect fluctuations in HepG2 cell metabol-
ism between the two cultivation rounds and the RNA
extraction. Given the high fraction of snoRNAs among
the differentially expressed genes, the fact that differential
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short genes [12] could also contribute to these differences;
however, the RPKM values for these snoRNA genes were
not outlying (Additional file 10: Figure S2). In contrast,
the differences between the preparation methods (HR_m
vs. HR_c) were much larger than those between the la-
boratories: 3,252 differentially expressed genes were iden-
tified. However, the analysis of this group of genes did not
reveal any biological relevance, consistent with the idea
that the source of the variation was primarily technical
and associated with the differences in the protocols’ steps
(see Additional file 2: Table S2). Notably, the workflow of
sample preparation method C is similar to the method
used for microarrays, potentially accounting for the lower
correlation between RNA-Seq using method M and mi-
croarrays than between method C and microarrays. Our
analysis was limited to examining two protocols in one la-
boratory and one of the protocols in another laboratory.
Obviously, a comparison of a greater number of protocols
in each of a greater number of laboratories is needed to
clarify the observed effects of these experimental factors.
Without denying the existence of protocols that do pro-
duce highly similar results, we would like to emphasize
that the significant differences observed between the two
established methods point out the need for a careful plan-
ning of sample preparation in RNA-Seq experiments.
The comparison of the HepG2 transcriptome obtained
using the SOLiD platform with the results of two pub-
lished studies based on the Illumina platform [8,9] showed
high correlation (r > 0.9), suggesting the consistency and
comparability of the RNA-Seq data generated using these
two prevalent high-throughput platforms, despite the ef-
fect of possible differences in biological material and sam-
ple preparation protocols. Importantly, the correlation
with Helicos sequencing results was also high, supporting
the comparability of the data obtained using amplification-
based and single-molecule sequencing approached. The
lower correlation with the microarray data was consistent
with the published differences between the two technolo-
gies for expression profiling [9].
An omics-based comparison of the liver tissue (hepa-
tocytes) with traditional cell models is crucial for asses-
sing the potential limitations of the in vitro experiments.
Here, we compared the HepG2 transcriptomic signature
with that obtained with liver tissue biopsy material [7].
The majority of the genes that were up-regulated in
HepG2 cells were associated with cancer, while the genes
that were up-regulated in the liver were associated with
xenobiotic metabolism. Considering these large groups,
researchers should be wary when designing transcrip-
tomic experiments using HepG2 cells as a liver model. If
the target genes are associated with the oncology of
interest, then the expression levels of these genes will be
a strongly biased estimate of their levels in the liver. Thisfact has important implications for drug, toxicity and car-
cinogenicity testing. In addition, the increased levels of the
genes associated with xenobiotic inactivation in the liver
transcriptome could reflect the fact that the samples were
biopsies obtained from the patients who were likely to re-
ceive medical treatment.
We compared the list of the genes that were differen-
tially expressed between HepG2 cells and the liver (SOLiD
RNA-Seq) to the corresponding results obtained in an-
other study of HepG2 cells and hepatocytes using micro-
arrays [13]. The analysis revealed that 27 of the 50 genes
that were up-regulated and 271 of the 608 genes that were
down-regulated in HepG2, as assessed using the RNA-
Seq, were also detected using microarrays (among the
3,559 up-regulated and 2,540 down-regulated genes, re-
spectively). None of the up-regulated genes identified in
RNA-Seq was among the down-regulated genes identified
through microarray, and only 2 of the down-regulated
genes were among the up-regulated genes detected by
microarray. While the RNA-Seq analysis was more spe-
cific, and the number of differentially expressed genes
identified in the RNA-Seq analysis was an order of magni-
tude lower, the significance testing confirmed the general
consistency of the results from the two studies (Pearson’s
chi-squared test with simulated p-value, chi-squared =
1183.63, p = 5E-4; see Methods for details).
A majority of the 23 genes that were up-regulated in
HepG2 cells, identified through RNA-Seq but not micro-
array analysis, encoded proteins that are associated with
active mitotic cell division, particularly the M phase of
the mitotic cell cycle. This finding is logically explained
by the biological difference between the samples com-
pared in the two studies: in the present study, we com-
pared a growing HepG2 cell line with a stationary liver
biopsy sample, while Costantini et al. [13] compared two
cell lines, each dividing at a different rate; thus, these
genes were not differentially expressed.
In contrast, among the 391 genes that were down-
regulated in HepG2 cells, identified through RNA-Seq
but not microarray analysis, the largest group (181/391,
46.3%) was associated with the GO category “response
to any stimulus”, with a majority of the genes respon-
sible for detoxification. The next largest group com-
prised 71 genes (18.2%) belonging to the GO term
“immune system process”. A high proportion of these
genes are involved in the synthesis of blood plasma
proteins and components of the immune system. Both
of these processes are physiological functions of the
liver under normal conditions. Therefore, the reduced
expression of these genes in HepG2 cells compared
with liver tissue is logical. The conditions for hepatocyte
cultivation in vitro might have led to inactivation of these
metabolic pathways, thus decreasing the differences in the
HepG2 cell line.
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technology and differences in the biological objects, other
factors likely contribute to the variations between the two
studies. One factor is the availability of biological repli-
cates: Costantini et al. [13] included 4 replicates per group,
but these replicates were technical, not biological. In con-
trast, in the present RNA-Seq study, we had 1 sample for
liver and 2 biological replicates for HepG2 cells. The avail-
ability of these biological replicates, i.e., two HepG2 sam-
ples from two different laboratories, allowed a more
specific detection of the HepG2 gene expression signature
based on the natural variability of the biological object.
This fact must have contributed to the identification of
a lower number of differentially expressed genes in the
present study.
Secondly, the statistical models were quite different be-
tween the studies. Specifically, Costantini et al. [13] used
an “Illumina Custom” error model, which considers the
gene levels to be distributed normally across the biological
replicates; the details about the multiple testing adjust-
ment were not specified. In the present study, we used
edgeR software, which accounts for overdispersion across
biological replicates, with application of multiple testing
correction to the resulting gene list (FDR method). This
approach implies a higher specificity of the resulting set of
differentially expressed genes.
Conclusions
In the present study, we demonstrated that the transcrip-
tomic profiles obtained using RNA-Seq are generally
invariant across the sequencing platforms (SOLiD and
Illumina) and are reproducible for HepG2 cell lines
across different laboratories. An evaluation of the experi-
mental factors showed that the sample preparation proto-
col is the strongest factor influencing the gene expression
profile.
We identified the characteristic differences in gene
expression between HepG2 cells and liver tissue. Although
most genes showed insignificant changes, the genes show-
ing significantly different expression outline the cancer-
associated signature that should be highly considered
when choosing the application of HepG2 cells as a model
system for liver transcriptomics.
Comparisons with other studies showed that the SOLiD
sequencing data are consistent with previous results and
can be used in future studies as an external control for es-
timating biological variability and the quality of new data
to optimize experimental design, including the calculation
of coverage depth and number of replicates.
Methods
Cell culture
The human hepatocellular carcinoma HepG2 cell line
was obtained from the collection of the OrekhovichInstitute of Biomedical Chemistry (IBMC). Frozen cells
were thawed and expanded in DMEM/F12 supplemented
with 10% fetal bovine serum (FBS) and 100 units/ml
penicillin/streptomycin (all from Gibco, Carlsbad, CA)
in a humidified CO2 incubator under standard condi-
tions (5% CO2, 37°C).
RNA isolation and analysis
Total RNA was isolated from the HepG2 cells using the
RNeasy mini kit (Qiagen GMBH, Hilden, Germany)
according to the manufacturer’s instructions, yielding
150 μg of total RNA. The amount of total RNA was de-
termined using a NanoDrop 1000 spectrophotometer
(NanoDrop, Wilmington, DE). The quality of the RNA
preparation was evaluated using the Agilent RNA 6000
Nano Kit on an Agilent Bioanalyzer 2100 system (Agilent,
Palo Alto, CA). The quality of the preparation was consid-
ered to be high based on an RIN value of 8.7.
mRNA enrichment
mRNA was enriched from total RNA using the Micro-
Poly(A)Purist Kit (Ambion by Life Technologies, Houston,
TX, USA) in triplicate according to the manufacturer’s in-
structions. Two rounds of enrichment were performed.
The RNA concentration was measured using a Qubit 2.0
Fluorometer (Life Technologies, Carlsbad, CA) with the
Quant-iT RNA Assay Kit, 5–100 ng. The RNA quality
and rRNA depletion were estimated using the 2100
Bioanalyzer system (Agilent Technologies) and the RNA
6000 Pico kit. A total of 1.1, 1.4 and 1.4 μg of mRNA
was obtained from 150 μg total RNA.
Library preparation and RNA sequencing
The mRNA fragment library was prepared using the
SOLiD Total RNA-Seq Kit (Ambion) according to the
manufacturer’s instructions. The mRNA fragment library
was sequenced on a SOLiD 4 platform (Life Technolo-
gies) according to the manufacturer’s instructions, with
three technical replicates (sample identifiers: HI1, HI2,
HI3; group identifier: HI). The length of each read was
50 bp.
Droplet digital PCR (ddPCR)
For cDNA preparation and ddPCR, the RNA was treated
with DNase I (Thermo Fisher Scientific, Waltham, MA)
and subsequently used for cDNA synthesis with H-minus
Mu-MLV reverse transcriptase (Thermo Fisher Scientific)
and random hexanucleotides according to the manufac-
turer’s instructions. The ddPCR reaction mixtures were
prepared in 20-μl volumes containing 1X ddPCR Super-
mix (Bio-Rad Laboratories, Hercules, CA), 0.3 μM of each
primer and probe (Additional file 1: Table S1), and 0.6-
1 μg of cDNA. The droplet generation and droplet reading
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turer’s instructions using Bio-Rad reagents.
Read mapping and gene expression analysis
The color-space reads were mapped to the human gen-
ome (version hg18) using Lifescope software (Life Tech-
nologies) with RefSeq genome annotation obtained from
the UCSC browser, yielding both raw read counts and
RPKM values for each of the 24,628 genes. The statis-
tical analysis was performed in R [14]. Differential gene
expression was analyzed using two methods. When at
least two biological replicates were available for at least
one comparison group (i.e., analysis between the liver
and cell line samples), the analysis was performed using
the edgeR package [15] based on read counts (multiple
comparison adjustment correction was performed using
the false discovery rate [FDR]; the difference was consid-
ered significant if the adjusted p-value did not exceed
0.05). In other cases, the log of the RPKM fold-change
for each gene between the two samples was assessed for
the major genes (genes expressed in both samples, with
an RPKM higher than a threshold value in at least one
sample). The gene set enrichment analysis was performed
using WebGestalt [16], with the Entrez Gene set as a
reference, using a hypergeometric test with Benjamini-
Hochberg multiple comparison adjustment correction
(significance criterion: adjusted p-value adjP < 0.05) and
the maximum number of significant hits M = 40.
Comparison with the published data
For comparison of the Illumina datasets with the SOLiD
gene expressions profiles, the EnsEMBL gene names
available for the ENCODE (GENCODE annotation) and
van Delft et al. (EnsEMBL v58 genome) data were con-
verted to HGNC gene names using biomaRt R package.
For comparison of the four microarray datasets down-
loaded from GEO with the SOLiD gene expressions pro-
files, the microarray gene expression levels were averaged
across the probes and assigned HGNC gene names using
GEOquery R package.
To check the general consistency of the differential
expression analysis results obtained in our study using
RNA-Seq and in the study of Costantini et al. [13] using
microarrays, we considered the direction of change (if
detected) for each of the genes that were included in the
RefSeq annotation for RNA-Seq (n = 24,628). For RNA-Seq,
the genes up-regulated in HepG2 cell line in comparison
with the liver were assigned tag “1” and the down-regulated
genes “-1”; all the other genes were assigned “not signifi-
cant” tag. The same procedure was performed for mi-
croarrays (after the conversion of the gene names from
microarrays that were not found in the RefSeq annota-
tion using org.Hs.eg.db R package). The resulting two
vectors of length l = 24,628 were transformed into 3 × 3contingency table and tested for independence using
Pearson’s chi-squared test with simulated p-value (based
on 2,000 replicates).Availability of supporting data
The SOLiD sequence data (HI and HR_m) are available
in the Sequence Read Archive: SRA accession numbers
SRR1047450 and SRR1254936, respectively. The Helicos
sequence data are available at http://download.ripcm.com/
HepG2_article/.Additional files
Additional file 1: Table S1. ddPCR gene copy number.
Additional file 2: Table S2. Step-by-step comparison of the two
sample preparation protocols used for SOLiD RNA-Seq.
Additional file 3: Table S3. List of the housekeeping genes.
Additional file 4: Table S4. Change of gene expression associated with
various factors. a. List of the housekeeping genes for the datasets from
two laboratories (HI and HR_m), with the RPKM and log2 fold change. b.
List of the most variable genes between the datasets from two
laboratories (HI and HR_m), with the RPKM and absolute value of log2
fold change. Table S4c. List of the housekeeping genes for the datasets
with two sample preparation methods (HR_c and HR_m), with the RPKM
and log2 fold change. Table S4d. List of the most variable genes
between the datasets obtained with two sample preparation methods
(HR_c and HR_m), with the RPKM and absolute value of log2.
Additional file 5: Table S5. Spearman correlation of HepG2 gene
expression levels between SOLiD and Helicos.
Additional file 6: Table S6. Spearman correlation between the SOLiD
gene expression profiles and the published Illumina RNA-Seq and microarray
datasets.
Additional file 7: Figure S1. Hierarchical dendrogram of Spearman
correlation between SOLiD, Illumina and microarray gene expression
levels.
Additional file 8: Table S7. Genes differentially expressed in cultured
HepG2 cells in comparison to the liver. a. List of genes that were
upregulated in cultured HepG2 cells in comparison to the liver (including
the log2-fold-change in liver relative to HepG2, the average log2-counts-
per-million, the two-sided p-value and its adjusted version, with cutoff
FDR > 0.1). b. List of genes that were upregulated in the liver in comparison
to the cultured HepG2 cells (including the log2-fold-change in liver relative
to HepG2, the average log2-counts-per-million, the two-sided p-value and
its adjusted version, with cutoff FDR > 0.1).
Additional file 9: Table S8. Enrichment analysis of differentially
expressed genes. a. Gene Ontology (GO) terms enriched in HepG2 cells
in comparison to the liver according to WebGestalt analysis. b. Disease-
associated gene sets enriched in HepG2 cells in comparison to the liver
according to WebGestalt analysis. Table S8c. Gene Ontology (GO) terms
enriched in the liver in comparison to HepG2 cells according to WebGestalt
analysis. Table S8d. KEGG pathways enriched in the liver in comparison to
HepG2 cells according to WebGestalt analysis.
Additional file 10: Figure S2. Plot of gene length vs. RPKM value for
HI1 and HR_m samples.Abbreviations
RNA-Seq: RNA sequencing; RT-PCR: Real-time polymerase chain reaction;
ddPCR: Droplet digital PCR; RPKM: Reads per kilobase model per million
mapped reads; FDR: False discovery rate; KEGG: Kyoto Encyclopedia of Genes
and Genomes; SRA: Sequence Read Archive; ENCODE: The Encyclopedia of
DNA Elements; GTF: General Transfer Format; GEO: Gene Expression
Omnibus; GO: Gene Ontology.
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